|DB00182||Amphetamine||Amphetamine is indicated for the treatment of attention-deficit/hyperactivity disorders (ADHD) as well as for the treatment of central nervous system disorders such as narcolepsy.[A18540]
ADHD is a complex disorder associated with the substantial heterogeneity in etiology, clinical presentation, and treatment outcome. ADHD comes from a complex interplay between interdependent genetic and non-genetic factors which cause complex mental disorders in children and teenagers.[A174271]
On the other hand, narcolepsy is a chronic sleep disorder typically resenting during adolescence and characterized by excessive daytime sleepiness.[A174274]
Amphetamine is also being used nowadays off-label for the treatment of obesity, depression and chronic pain.[A174268, A174283]|
|DB00201||Caffeine||For management of fatigue, orthostatic hypotension, and for the short term treatment of apnea of prematurity in infants.|
|DB00422||Methylphenidate||For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.|
|DB00745||Modafinil||To improve wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy.|
|DB01230||Pemoline||For treatment of Attention Deficit Hyperactivity Disorder (ADHD)|
|DB01255||Lisdexamfetamine||For the treatment of Attention-deficit/hyperactivity disorder (ADHD) and for moderate to severe binge eating disorder in adults [FDA label], [A40246].
This drug is not indicated for weight loss. Use of other sympathomimetic drugs for weight loss is associated with serious cardiovascular effects. The safety and effectiveness of this drug for the treatment of obesity have not yet been determined [FDA label].
|DB01463||Fencamfamine||For the the treatment of depressive fatigue in convalescence and other debilitated states as well as in the treatment of depressive day-time fatigue, lack of concentration and lethargy.|
|DB01576||Dextroamphetamine||Used to treat attention deficit hyperactivity disorder (ADHD).|
|DB01577||Metamfetamine||For the treatment of Attention Deficit Disorder with Hyperactivity (ADHD) and exogenous obesity.|
|DB06413||Armodafinil||Investigated for use/treatment in sleep disorders, obstructive sleep apnea, schizophrenia and schizoaffective disorders, depression, and bipolar disorders.|
|DB06479||Propentofylline||Investigated for use/treatment in alzheimer's disease.|
|DB06701||Dexmethylphenidate||Dexmethylphenidate is used as a treatment for ADHD, ideally in conjunction with psychological, educational, behavioral or other forms of treatment.|
|DB08842||Acetylcarnitine||Acetylcarnitine is not approved for any indication in the United states and Canada, but it is approved and indicated in Italy for cerebrovascular disorders, mental function disorders, peripheral nerve disorders, diabetic neuropathy, and nutritional supplementation; Portugal for mental function disorders; Argentina for cerebral vasculopathy, nutritional supplementation, and peripheral neuropathy; Chile for dementia; Philippines for cerebrovascular disorders and mental function disorders; Australia for nutritional supplementation; and India for nutritional supplementation to increase sperm count. Acetylcarnitine also has several potential therapeutic indications for which it is still being investigated: in Norway, acetylcarnitine is in a phase IV trial for prophylactic treatment of migraines; in Italy acetylcarnitine is in a phase II trial for use in patients with type 2 Diabetes Mellitus, a phase III trial for alleviating fatigue in patients with chronic hepatitis C, and for use in patients with Minimal Hepatic Encephalopathy; in the United States acetylcarnitine is in a phase II trial for the neurodegenerative disorder Progressive Supranuclear Palsy, a phase II and III trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy, a phase I and II trial for treating patients in septic shock, a phase II trial for bipolar depression, a phase II trial to reduce oxidative stress in patients with Sickle Cell disease, a phase I and II trial for chronic fatigue syndrome, and a study for preventing nerve damage in HIV patients; in China acetylcarnitine is in a phase III trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy; in the United Kingdom acetylcarnitine is being investigated for preventing nerve damage in HIV patients; and in Israel acetylcarnitine is being studied for the treatment of male infertility.
|DB08925||Adrafinil||Used to relieve excessive sleepiness and inattention in elderly patients.|
|DB09081||Idebenone||Idebenone is indicated for use by the European Medicines Agency (EMA) for the treatment of visual impairment in adolescent and adult patients with
Leber’s Hereditary Optic Neuropathy (LHON). It is not currently approved for use by either the Food and Drug Administration (USA) or Health Canada [L885].|
|DB09210||Piracetam||Indicated in adult patients suffering from myoclonus of cortical origin, irrespective of aetiology, and should be used in combination with other anti-myoclonic therapies [L1125].|
|DB11584||Pipradrol||Used to manage fatigue [L2522] and depression [L2515], [A32724], [L2518], [L2523]. Used as an adjunct therapy in the management of obesity [L2522].|
|DB00289||Atomoxetine||Atomoxetine is recommended for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults. It is recommended as a monotherapy in youths that do not respond correctly to stimulants.[A175723]
ADHD is a neurodevelopmental disorder that can be categorized as a mental health condition. The symptoms of this condition start at childhood but they continue in adolescence and adulthood. The risk factors of ADHD are variable and they include the consumption of cigarettes, alcohol or drugs during pregnancy, low brain weight, brain injuries, toxical exposure or genetic disorders. The main symptoms for this condition are difficult in paying attention, overactivity and impulsivity.[L5665]|